# MGX (Metagenomi Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Metagenomi Therapeutics, Inc. reported $25.21M in revenue and a net loss of $94.19M for the fiscal year ended December 31, 2025 (down 51.8% year over year), with a -396.5% operating margin.

- Canonical: https://convexityos.com/fundamentals/MGX
- Markdown: https://convexityos.com/fundamentals/MGX.md
- SEC CIK: 0001785279
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:02 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001785279&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $25.21M | -51.8% YoY |
| Operating Income | FY 2025 | -$99.95M | -396.5% margin |
| Net Income | FY 2025 | -$94.19M | -373.6% net margin |
| Diluted EPS | FY 2025 | -$2.49 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$83.53M | -331.3% FCF margin |
| Cash & ST Investments | Sep 30, 2026 | $101.7M | Total debt: $36.21M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Revenue** | $25.21M | $52.30M | $44.76M |
| Research & Development | $94.43M | $109.2M | $94.40M |
| Total Operating Expenses | $121.2M | $141.2M | $123.2M |
| **Operating Income** | -$96.01M | -$88.90M | -$78.49M |
| **EBITDA** | -$90.70M | -$83.49M | -$74.28M |
| Interest Income | $9.47M | $14.72M | $15.47M |
| Income Before Tax | -$87.93M | -$83.57M | -$60.23M |
| Income Tax Expense | -$58K | -$5.51M | $8.03M |
| **Net Income** | -$87.87M | -$78.06M | -$68.25M |
| Basic EPS | -$2.36 | -$2.36 | -$20.05 |
| **Diluted EPS** | -$2.36 | -$2.36 | -$20.05 |
| Basic Shares Outstanding | 37.3M | 33.0M | 3.4M |
| Diluted Shares Outstanding | 37.3M | 33.0M | 3.4M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $2.18M | -- | $1.25M | $3.91M | $8.66M | $8.51M | $4.13M | $9.61M |
| Research & Development | $17.53M | $22.51M | $19.30M | $21.50M | $25.28M | $22.51M | $25.14M | $23.16M |
| Total Operating Expenses | $24.41M | $28.52M | $25.84M | $28.28M | $31.50M | $29.50M | $31.95M | $30.24M |
| **Operating Income** | -$22.23M | -$28.77M | -$24.59M | -$24.37M | -$22.84M | -$20.99M | -$27.82M | -$20.62M |
| **EBITDA** | -$20.97M | -$27.51M | -$23.31M | -$23.07M | -$21.52M | -$19.65M | -$26.46M | -$19.16M |
| Interest Income | $1.05M | $1.26M | $1.54M | $1.88M | $2.21M | $2.48M | $2.89M | $3.20M |
| Income Before Tax | -$21.13M | -$27.48M | -$23.05M | -$22.49M | -$20.63M | -$19.86M | -$24.94M | -$24.61M |
| Income Tax Expense | $0 | $0 | $10K | $34K | -$234K | $44K | $98K | -$1.21M |
| **Net Income** | -$21.13M | -$27.48M | -$23.06M | -$22.53M | -$20.39M | -$19.91M | -$25.04M | -$23.40M |
| Basic EPS | -$0.56 | -$0.73 | -$0.61 | -- | -$0.55 | -$0.54 | -$0.68 | -- |
| **Diluted EPS** | -$0.56 | -$0.73 | -$0.61 | -- | -$0.55 | -$0.54 | -$0.68 | -- |
| Basic Shares Outstanding | 37.8M | 37.7M | 37.6M | -- | 37.3M | 37.2M | 37.0M | -- |
| Diluted Shares Outstanding | 37.8M | 37.7M | 37.6M | -- | 37.3M | 37.2M | 37.0M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $41.72M | $27.39M | $140.6M |
| Short-Term Investments | $119.1M | $220.9M | $130.6M |
| **Cash & Short-Term Investments** | $160.8M | $248.3M | $271.2M |
| Accounts Receivable, Net | $305K | $1.10M | $2.45M |
| **Total Current Assets** | $165.5M | $258.0M | $278.3M |
| Property, Plant & Equipment, Net | $12.29M | $17.74M | $21.54M |
| Long-Term Investments | $2.15M | $3.45M | $10.68M |
| Other Non-Current Assets | $836K | $287K | $5.49M |
| **Total Non-Current Assets** | $55.56M | $66.64M | $86.57M |
| **Total Assets** | $221.1M | $324.6M | $364.8M |
| Accounts Payable | $1.49M | $533K | $1.79M |
| Deferred Revenue (Current) | $8.70M | $22.76M | $48.07M |
| **Total Current Liabilities** | $22.93M | $37.31M | $68.86M |
| Deferred Revenue (Non-Current) | $2.99M | $10.24M | $30.93M |
| Other Non-Current Liabilities | $1.95M | $2.01M | $5.08M |
| **Total Non-Current Liabilities** | $39.57M | $52.43M | $80.81M |
| **Total Liabilities** | $62.51M | $89.74M | $149.7M |
| **Total Debt (incl. Leases)** | $40.66M | $45.78M | $48.23M |
| Common Stock | $4.0K | $4.0K | $0 |
| Retained Earnings | -$310.9M | -$223.0M | -$144.9M |
| Accumulated Other Comp. Income | $260K | $709K | -$97K |
| **Total Stockholders' Equity** | $158.6M | $234.9M | -$135.6M |
| Total Equity | $158.6M | $234.9M | -$135.6M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $36.11M | $39.03M | $25.31M | $41.72M | $32.77M | $26.85M | $29.20M | $27.39M |
| Short-Term Investments | $65.57M | $81.64M | $114.9M | $119.1M | $151.3M | $178.1M | $196.8M | $220.9M |
| **Cash & Short-Term Investments** | $101.7M | $120.7M | $140.2M | $160.8M | $184.1M | $205.0M | $226.0M | $248.3M |
| Accounts Receivable, Net | $0 | $0 | $0 | $305K | $960K | $900K | $900K | $1.10M |
| **Total Current Assets** | $110.9M | $124.5M | $144.6M | $165.5M | $189.8M | $211.7M | $233.2M | $258.0M |
| Property, Plant & Equipment, Net | $8.62M | $9.90M | $11.16M | $12.29M | $13.89M | $15.11M | $16.52M | $17.74M |
| Long-Term Investments | $2.15M | $2.15M | $2.15M | $2.15M | $2.15M | $2.15M | $3.45M | $3.45M |
| Other Non-Current Assets | $988K | $1.02M | $927K | $836K | $809K | $805K | $781K | $287K |
| **Total Non-Current Assets** | $46.53M | $49.23M | $52.40M | $55.56M | $58.12M | $60.60M | $64.67M | $66.64M |
| **Total Assets** | $157.4M | $173.7M | $197.0M | $221.1M | $247.9M | $272.3M | $297.9M | $324.6M |
| Accounts Payable | $773K | $2.60M | $2.40M | $1.49M | $1.22M | $2.89M | $2.67M | $533K |
| Deferred Revenue (Current) | $9.01M | $11.20M | $9.31M | $8.70M | $12.90M | $18.94M | $25.50M | $22.76M |
| **Total Current Liabilities** | $32.34M | $27.63M | $22.50M | $22.93M | $29.58M | $33.27M | $39.89M | $37.31M |
| Deferred Revenue (Non-Current) | $0 | $0 | $1.64M | $2.99M | $1.90M | $3.55M | $4.37M | $10.24M |
| Other Non-Current Liabilities | $2.02M | $2.02M | $1.95M | $1.95M | $1.92M | $2.15M | $2.11M | $2.01M |
| **Total Non-Current Liabilities** | $31.86M | $33.50M | $36.67M | $39.57M | $39.91M | $43.19M | $45.31M | $52.43M |
| **Total Liabilities** | $64.20M | $61.13M | $59.17M | $62.51M | $69.49M | $76.45M | $85.21M | $89.74M |
| **Total Debt (incl. Leases)** | $36.21M | $37.72M | $39.19M | $40.66M | $41.66M | $42.99M | $44.44M | $45.78M |
| Common Stock | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K |
| Retained Earnings | -$382.5M | -$361.4M | -$333.9M | -$310.9M | -$288.3M | -$267.9M | -$248.0M | -$223.0M |
| Accumulated Other Comp. Income | -$159K | -$122K | -$44K | $260K | $371K | $372K | $621K | $709K |
| **Total Stockholders' Equity** | $93.19M | $112.6M | $137.8M | $158.6M | $178.4M | $195.8M | $212.7M | $234.9M |
| Total Equity | $93.19M | $112.6M | $137.8M | $158.6M | $178.4M | $195.8M | $212.7M | $234.9M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$87.87M | -$78.06M | -$68.25M |
| Depreciation & Amortization | $5.32M | $5.41M | $4.21M |
| Stock-Based Compensation | $11.85M | $16.20M | $6.92M |
| Change in Receivables | $952K | $1.19M | -$2.45M |
| Change in Payables | $1.05M | -$1.11M | -$84K |
| **Operating Cash Flow** | -$88.89M | -$109.1M | -$91.41M |
| Capital Expenditure | -$574K | -$3.11M | -$9.81M |
| **Free Cash Flow** | -$89.47M | -$112.2M | -$101.2M |
| Purchases of Investments | -$66.41M | -$306.1M | -$208.1M |
| **Investing Cash Flow** | $103.5M | -$88.16M | $45.73M |
| **Financing Cash Flow** | -$356K | $84.01M | $1.01M |
| **Net Change in Cash** | $14.28M | -$113.2M | -$44.66M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$21.13M | -$27.48M | -$23.06M | -$22.53M | -$20.39M | -$19.91M | -$25.04M | -$23.40M |
| Depreciation & Amortization | $1.25M | $1.26M | $1.27M | $1.30M | $1.32M | $1.33M | $1.36M | $1.46M |
| Stock-Based Compensation | $1.78M | $2.27M | $2.55M | $2.69M | $3.01M | $3.22M | $2.93M | $3.41M |
| Change in Receivables | $0 | $0 | $305K | $655K | -$87K | $139K | $245K | -$668K |
| Change in Payables | -$1.83M | $319K | $795K | $346K | -$1.58M | $74K | $2.21M | -$2.57M |
| **Operating Cash Flow** | -$19.08M | -$19.51M | -$21.18M | -$23.55M | -$21.25M | -$21.25M | -$22.84M | -$26.28M |
| Capital Expenditure | $21K | -$125K | -$25K | -$85K | -$74K | -$127K | -$288K | -$334K |
| **Free Cash Flow** | -$19.06M | -$19.64M | -$21.20M | -$23.63M | -$21.33M | -$21.38M | -$23.13M | -$26.61M |
| Purchases of Investments | -$13.66M | -$3.91M | -$36.75M | -$19.55M | -$6.06M | -$18.51M | -$22.29M | -$12.34M |
| **Investing Cash Flow** | $16.16M | $33.17M | $3.99M | $32.37M | $27.36M | $19.07M | $24.73M | $28.55M |
| **Financing Cash Flow** | $0 | $67K | -$27K | $74K | -$187K | -$166K | -$77K | $0 |
| **Net Change in Cash** | -$2.92M | $13.72M | -$17.22M | $8.89M | $5.92M | -$2.35M | $1.81M | $2.27M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Operating Margin** | -380.9% | -170.0% | -175.4% |
| **Net Profit Margin** | -348.5% | -149.3% | -152.5% |
| Return on Equity (ROE) | -55.4% | -33.2% | -- |
| Return on Assets (ROA) | -39.7% | -24.0% | -18.7% |
| Current Ratio | 7.22x | 6.91x | 4.04x |
| Quick Ratio | 7.03x | 6.68x | 3.97x |
| Debt to Equity | 0.26x | 0.19x | -- |
| **Revenue Growth (YoY)** | -51.8% | +16.8% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -415.5% | -380.9% | -298.5% | -271.9% | -193.7% | -170.0% |
| **Net Profit Margin** | -- | -- | -384.6% | -348.5% | -287.1% | -258.0% | -172.2% | -149.3% |
| Return on Equity (ROE) | -101.1% | -83.0% | -62.3% | -55.4% | -49.7% | -44.5% | -36.7% | -33.2% |
| Return on Assets (ROA) | -59.8% | -53.8% | -43.6% | -39.7% | -35.8% | -32.0% | -26.2% | -24.0% |
| Current Ratio | 3.43x | 4.50x | 6.43x | 7.22x | 6.42x | 6.36x | 5.85x | 6.91x |
| Quick Ratio | 3.14x | 4.37x | 6.23x | 7.03x | 6.26x | 6.19x | 5.69x | 6.68x |
| Debt to Equity | 0.39x | 0.34x | 0.28x | 0.26x | 0.23x | 0.22x | 0.21x | 0.19x |
| **Revenue Growth (YoY)** | -74.8% | -- | -69.8% | -59.3% | -24.8% | -57.5% | -63.0% | -22.5% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
